A new permanent commissioner at the Food and Drug Administration will need to bring more clarity to the government’s pandemic response and restore trust to an agency that remains without a Senate-confirmed leader nearly a year into the Biden administration, policy analysts and former FDA officials say.
President Joe Biden has just weeks left to name a replacement for acting Commissioner Janet Woodcock, who was ruled out for the post due to opposition on Capitol Hill. Installing a permanent head is seen as necessary to bring a steady presence amid the ever-evolving conditions of the pandemic.
“It’s hard to have ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.